Cilomilast

Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders… Expand

Psoriasis and psoriatic arthritis are common clinical conditions that negatively impact health-related quality of life and are… Expand

Background COPD is a relentless, progressive disease. This study evaluated the efficacy of cilomilast, a selective… Expand

Inhibitors of phosphodiesterase type 4 (PDE4) act by increasing intracellular concentrations of cyclic AMP, which has a broad… Expand

Cilomilast (Ariflo), a new oral phosphodiesterase-4 selective inhibitor, improves lung function in chronic obstructive pulmonary… Expand

Background: Inflammation in chronic obstructive pulmonary disease (COPD) is characterised by increased neutrophilic infiltration… Expand

Phosphodiesterase (PDE) enzymes are responsible for the inactiviation of cyclic adenosine monophosphate (cAMP) and cyclic… Expand

BACKGROUND Chronic obstructive pulmonary disease (COPD) is a common, progressive respiratory disease that causes great morbidity… Expand

From a series of benzamide derivatives, roflumilast (3-cyclo-propylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl… Expand

Cilomilast (Ariflo™ , SB-207499) is an orally-active, second generation phosphodiesterase (PDE) inhibitor that may be effective… Expand